CTRI/2022/01/039575尚未招募3 期
A randomized, open label, multi-center, two arm, comparative efficacy study of Zydus Wellness product ZW3015829 in healthy, children of age 6 to 18 years.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female child between 6 years to 18 years of age.
- •2. Parents providing written informed consent and are willing to participate in the study.
- •3. Providing accent for trial (if participant age >11 years of age)
- •4. Parent agrees to provide milk/product as instructed.
- •5. No any active sign/symptom of illness, disease or disorder or any co morbidities such as IDDM as evaluated by Physician.
排除标准
- •1. Child who has hypersensitivity to any drug or food product or nutritional product or Ayurvedic product.
- •2. Child taking medicine for any disease or disorder.
- •3. Child diagnosed with clinical disease or disorder including malnutrition or anemia which require therapeutic treatment.
- •4. Child with history of surgery within last 3 months of participation.
- •5. Child participated in any other clinical trial within last 3 months.
- •6. Investigator opinion on any foreseen subject non-compliances towards study protocol during the study execution.
- •7. Child height or weight is less than 13 percentile as per Indian Khadilkar Growth Chart.
研究者
相似试验
尚未招募
3 期
controlled trial of SHIRO KLOMAN treatment in mild to moderate symptomatic patients with SARS-CoV-2 Infection (Covid-19).CTRI/2021/09/036100Bindi Prashant Shah
招募中
2 期
Role and effect of Capsule HRPT-091514 as an add treatment to normal standard treatment in patient with chronic kidney disease.CTRI/2020/12/029519The Himalaya Drug Company
已完成
4 期
A multicenter, two arm, randomized, open label clinical study investigating renal function in an advagraf®-based immunosupressive regimen with or without sirolimus in kidney transplant subjects.Kidney transplantationtransfer of a healthy kidney in another body with non-functioning kidneys.10029149NL-OMON38063Astellas Pharma B.V.30
进行中（未招募）
不适用
A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the first 6 months post-transplantation when treated with an immunosuppressive regimen including everolimus (Certican®) and reduced dose of cyclosporine A (Néoral®) versus an immunosuppressive regimen with mycophenolic acid (Myfortic®) and standard dose of cyclosporine A (Néoral®). - EVERCMVCMV infection in CMV-seropositive de novo kidney transplant recipients receiving an immunosuppressive regimen.EUCTR2013-003195-12-FRCHU de Bordeaux
招募中
4 期
A study to Assess the Safety and Efficacy of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Lung Cancer patients.CTRI/2017/04/008305Intas Pharmaceuticals Ltd